The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
Greater visceral and thigh subcutaneous fat are associated with higher risks of advanced and fatal prostate cancer (PCa), according to a new prospective study. In addition, visceral fat is associated with a higher risk of these outcomes among men with a lower body mass index (BMI). Investigators found no association between any adiposity measure and…
No increased risk seen at posttreatment in children of fathers with testicular germ-cell cancer
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.